Description :The Mesenchymal Epithelial Transition (MET) receptor belongs to a family of Receptor tyrosinekinases (RTKs). The MET proto-oncogene is located on chromosome 7q21–31 and encodesthe receptor tyrosine kinase C-Met. It is a 190 kD glycoprotein heterodimer made up of anextracellular α-chain which is linked by a disulphide bond to a transmembrane β-chain. c-Met isinitially synthesised as a 170 kD single polypeptide as precursor that is proteolytically cleavedto form the α-chain and the β-chain. TPR-MET oncogenic fusion protein from humanosteosarcoma tumor cells was first discovered in 1984. c-Met is a hepatocyte growth factor(HGF) receptor. The initiation of MET signaling begins with the binding of HGF to the METreceptor at cell membrane that causes C-Met dimerization. Subsequent activation is through aprocess of trans-phosphorylation of the two tyrosine residues in the catalytical regions Y1234and Y1235, followed by trans-phosphorylation of two docking tyrosines (Y1349 and Y1356). Itenables MET to bind to multiple substrates and activate a variety of signaling pathways, suchas MAPK, PI3K-AKT cascades, STAT and NF-κB signaling pathways. This is responsible fordriving proliferation, cell survival, migration and invasiveness. c-Met is overexpressed indifferent human tumors, such as thyroid, gastric, pancreatic, breast, cervical and prostatecancers. Increasing evidence indicated that MET may be a common mechanism of resistanceto anticancer treatment such as approved EGFR and VEGFR inhibitors, anti-HER2 therapiesand a BRAF inhibitor. Hence, the HGF-MET axis has been targeted in solid tumors toovercome the drug resistance.
Verified Reactivity :Human
Antibody Type :Monoclonal
Host Species :Mouse
Immunogen :Bacterially expressed human c-Met alpha chain.
Recommended Usage :Each lot of this antibody is quality control tested by Western blotting. For Western blotting, thesuggested use of this reagent is 0.5 - 2.5 µg per ml. It is recommended that the reagent be titratedfor optimal performance for each application.